Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 17/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17220660 | 0.75 | NR1H2 (0.59) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL1928501 | 0.73 | IKBKB (0.47) | IKBKBJAK2JAK3CHEK1 | |
| SCHEMBL14367891 | 0.72 | NR1H2 (0.75) | NR1H2NR1H3 | |
| SCHEMBL23380914 | 0.71 | NR1H2 (0.57) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL1929398 | 0.70 | CHEK1 (0.50) | IKBKBJAK2JAK3CHEK1 | |
| SCHEMBL7052335 | 0.70 | IKBKB (0.72) | IKBKBJAK2JAK3CHEK1 | |
| SCHEMBL5599682 | 0.69 | NR1H2 (0.56) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL4554717 | 0.69 | NR1H2 (0.60) | NR1H2NR1H3CA12CA9 | |
| SCHEMBL26670152 | 0.69 | NR1H2 (0.74) | NR1H2NR1H3 | |
| SCHEMBL17220643 | 0.69 | NR1H2 (0.74) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421079-B1 | THIOPHENYL COMPOUNDS AS MEDICAMENTS | ASTRAZENECA AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| US-7098240-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-08-29 | — | — | US | disclosed |
| US-20040235821-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235821-A1 | Novel compounds | ABCG2, UGT1A1, SULT1E1 | NR1H2 991/4885NR1H3 1183/4885IKBKB 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.